How GLP-1 medications affect your mitochondria

GLP-1 medications like Ozempic, Wegovy, and Mounjaro affect mitochondria by activating the AMPK and PGC-1α pathways, which improve energy production, trigger the growth of new mitochondria, and help convert energy-storing white fat into more metabolically active brown fat. 

This appears to mitigate things like oxidative stress, fragmented mitochondria, reduced fat-burning capacity that develop with excess weight. However, these same medications are also linked to muscle loss (largely driven by reduced calorie and protein intake) which can undermine mitochondrial health in muscle tissue if not actively managed through diet and resistance training. 

What you’ll learn 

• How GLP-1 medications like Ozempic, Wegovy, and Mounjaro affect mitochondrial function at a cellular level and why that matters for energy and metabolism 
• Why these medications are linked to muscle loss and what can help protect it 
• What happens to your metabolism when you stop taking a GLP-1, and how to prepare for that transition 
• What happens to mitochondria before you start a glp-1 
• Why carrying excess weight makes mitochondria less efficient 

Roughly 12% of Americans have taken a GLP-1 medication, and 6% are currently on one. Most of the conversation around GLP-1s focuses on appetite and weight - but there's a different story happening at the cellular level that explains a lot about why these medications work the way they do, and what can go wrong if you're not supporting your body properly while you're on them. To understand what GLP-1s are doing, it helps to understand what's already going wrong metabolically in someone who's overweight. 

As fat cells take on more energy than they can use, they expand - which is a process called hypertrophy. Cells that grow this large start to outstrip their own blood and oxygen supply, which starves the mitochondria inside them of what they need to produce energy efficiently. At the same time, the sheer volume of glucose and fat in the system can impact mitochondrial function and generate excess oxidative stress. 

The result is that mitochondria are simultaneously overloaded and undersupplied, which triggers what's known as an integrated stress response. 

The fat cell–mitochondria connection 

This stress response is supposed to trigger mitophagy - the process where damaged mitochondria get broken down and recycled. But in practice, the process often stalls halfway. Mitochondria become fragmented (split apart) without being properly cleared out or replaced, leaving cells full of small, dysfunctional mitochondria that struggle to communicate or share resources the way a healthy mitochondrial network normally would. 

These dysfunctional mitochondria are unable to metabolize fat as effectively, in part due to a decrease in beta-oxidation, which turns fatty acids into energy. This means that the fat stores are not used effectively as fuel, a core reason weight loss becomes so much harder to achieve in conditions like chronic obesity.  

Mitochondrial dysfunction is also tied to insulin resistance. A healthy insulin response is needed to maintain adequate blood sugar levels, and begin the process of converting sugars into fuel. Insulin release depends heavily on healthy mitochondrial function in the beta cells of the pancreas. 

This is part of why "calories in, calories out" doesn't tell the whole story. The biology of how the body actually metabolizes fuel is far more complex - and mitochondrial health is a big part of that missing piece. 

How GLP-1s affect mitochondrial function 

The AMPK and PGC-1α pathways explained 

GLP-1 medications appear to do more than suppress appetite, research shows they seem to the body at a cellular level. 

This happens through two important pathways. The first is AMPK, a pathway that signals to mitochondria that they need to boost energy production and adapt to stress in a beneficial way. The second is PGC-1α, a master regulator of mitochondrial biogenesis (the process of making new mitochondria). Activating this pathway means the body isn't just improving the mitochondria it has, it's building new mitochondria to replace the fragmented, under-functioning network built up during years of metabolic strain. There's also an interesting feedback loop in that people who are overweight tend to have blunted natural GLP-1 signalling, and GLP-1 medications appear to help restore that natural signalling over time. 

Can GLP-1s turn white fat into brown fat? 

One of the more surprising findings is that GLP-1s appear to encourage a shift from white adipose tissue (standard fat storage) toward brown adipose tissue. What’s special about brown adipose tissue is that it’s dense in mitochondria and burns energy specifically to generate heat, rather than storing it. When fat is burnt through heat production, this puts less demand on the mitochondria, and helps both reduce the size of fat cells and may also contribute to less oxidative stress. Recent research has shown people on GLP-1s developing more brown fat over time, which may be a meaningful, underappreciated contributor to their metabolic improvements. 

In animal studies, GLP-1 agonists like liraglutide have been shown to increase both the number and area of mitochondria in tissues including skeletal muscle, essentially restoring a more functional mitochondrial population across multiple organ systems - not just in fat cells. 

GLP-1s and Muscle Loss: What the Research Shows 

How much lean mass do you really lose on a GLP-1? 

This is one of the most debated areas in GLP-1 research. Some trials have reported roughly 10% reductions in lean mass over extended treatment periods, with other data suggesting lean mass can account for up to a quarter of total weight lost. There's also growing concern about what happens over multiple cycles of starting and stopping - anecdotally, weight regained after stopping a GLP-1 tends to return mostly as fat if an exercise regimen is not followed. Successive muscle loss and fat gain could compound lean mass loss over time, which can lead to further complications as we age. 

Are you eating enough protein on a GLP-1? 

A recent study using AI-powered nutrition tracking found people on GLP-1 medications averaging around 1,100 calories a day and 54g of protein - both notably lower than reported by non-users. Separately, a review of clinical studies found GLP-1 and dual GIP/GLP-1 therapies reduce total caloric intake by 16–39% compared to placebo. Separately, data presented at a recent Endocrine Society meeting found average daily step counts dropping from around 5,000 to roughly 4,400 among people on GLP-1s. 

If you're not eating enough (particularly enough protein) and you're moving less, you're going to lose muscle. That's true regardless of what's happening with the GLP-1 itself. Whether GLP-1s cause muscle loss beyond what calorie restriction alone would explain is still up for debate, but it’s clear is that under-eating and under-exercising will exacerbate an unhealthy body composition.  

A practical protein target: aim for 1.2–1.6g of protein per kilogram of your current body weight per day, prioritizing whole food sources (eggs, beans, lean meat). 

GLP-1s, dopamine, and motivation: the "ozempic personality" 

Why food noise (and food enjoyment) disappears 

The appetite suppression people feel on GLP-1s is largely dopamine-mediated. GLP-1s cause dopamine release in the reward centers of the brain to dampen, which explains why food noise fades. It also explains why cravings for other things, including alcohol, often fade too. 

The problem is that dopamine doesn't just drive craving, it drives motivation and the sense of reward. So, the same mechanism that quiets food noise can also blunt drive and enjoyment in other areas of life. 

The research on mood is mixed, but it’s worth being aware of. Some people experience less feelings of anxiety and improved mood as food-related stress lifts and weight reduces. But for people already prone to mood instability, the same motivation-blunting effect that quiets food noise may worsen low mood. One notable study using a reward-based effort task found people with depression showing improved motivation on semaglutide compared to placebo, suggesting the effect may vary significantly depending on someone's starting mental health status. Long-term data on how dopamine signalling changes with extended GLP-1 use is still limited. 

Unlike bariatric surgery which physically restricts food intake, GLP-1s appear to dial down the whole reward-seeking system. This is part of why the psychological experience of being on one can feel so different from other weight-loss approaches. 

How to support your mitochondria and muscle while on a GLP-1 

Protein targets to preserve muscle mass 

Aim for 1.2–1.6g/kg of current body weight per day, from whole foods where possible. This single factor appears to be one of the most controllable variables in whether muscle is preserved during treatment. 

Best supplements for mitochondrial health on GLP-1s 

A few supplements worth considering alongside diet and resistance training: 

Creatine: supports ATP buffering and recycling in muscle tissue, working alongside resistance training (not as a substitute for it) to help build and preserve lean mass. 

NAD+ precursors: NAD+ is essential for mitochondrial ATP production and tends to decline with both age and obesity-related disease, so replenishing it may support mitochondrial capacity. 

MitoQ® Mitoquinol: clinical research has linked Mitoquinol to improved muscle power output and increased muscle mitobiogenesis (formation of new mitochondria in muscle tissue).  

A multivitamin covering vitamin D, B12, potassium, and calcium: deficiencies in these are common in the both calorie and appetite restricted states that a GLP-1 creates. B12 absorption in particular can be affected by the reduced gut motility that comes with these medications. 

Why fiber is so important 

Fiber gets less attention than protein in most GLP-1 content, but it plays a direct role in restoring your body's own natural GLP-1 production - largely by feeding the short-chain-fatty-acid-producing bacteria in your gut. Probiotic strains like Akkermansia and certain lactobacillus species have also been linked to improved long-term GLP-1 signalling. 

Consider a baseline DEXA scan 

If you're starting a GLP-1, getting a baseline body composition scan (even before your first dose) gives you something concrete to track against, particularly for monitoring bone density and lean mass alongside fat loss over time. 

What happens to your metabolism when you stop taking a GLP-1 

Why weight regain isn’t just about appetite 

The return of food noise after stopping a GLP-1 is only part of the story. People with a history of being overweight tend to show methylation patterns that keep genes for fat metabolism (lipolysis), oxidative phosphorylation, and mitochondrial biogenesis somewhat suppressed for an extended period. Due to epigenetic changes, this can show up as people finding they can no longer eat the way their leaner friends do without regaining weight, even on a modest calorie intake. 

The best way to prepare coming off a GLP-1 is to establish the habits that support natural GLP-1 production and mitochondrial function before coming off the medication. Focus on increasing fiber intake, maintaining resistance training and keeping protein consistent. 

The bottom line 

GLP-1 medications appear to do more than suppress appetite. They seem to help repair mitochondrial function through pathways like AMPK and PGC-1α activation, improved respiratory function, and a possible shift toward metabolically active brown fat. But that potential benefit isn't automatic.

Without adequate protein, fiber and resistance training, the same medication that helps to repair your mitochondria can coincide with muscle loss, and the metabolic gains can be harder to hold onto once treatment stops. Supporting your mitochondria isn't a side project while you're on a GLP-1. It's a necessary tool to support your overall metabolic health and longevity. 

REFERENCES

• 1.

  KFF. (2024, May 10). KFF health tracking poll May 2024: The public's use and views of GLP-1 drugs. https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

• 2.

  Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019). A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinology and Metabolism, 34(3), 247–262. https://www.e-enm.org/journal/view.php?doi=10.3803%2FEnM.2019.34.3.247

• 3.

  Yang, X., Feng, P., Ji, R., Ren, Y., Wei, W., & Hölscher, C. (2016). Exenatide regulates lipid metabolism and browning through GLP-1 receptor-mediated SIRT1 signalling in mouse white adipose tissue. Diabetologia, 59(9), 1938–1948. https://link.springer.com/article/10.1007/s00125-016-3896-5

• 4.

  Bispham, N. Z., Hutton, D. A., Rosenberg, H. L., Chonchol, M., Seals, D. R., & Rossman, M. J. (2017). MitoQ supplementation improves leg-extension power in healthy late middle-aged and older adults. The FASEB Journal, 31(S1). https://doi.org/10.1096/fasebj.31.1_supplement.lb852

• 5.

  Peeples, J. (2024, April 23). 'Ozempic personality': How weight loss drugs can affect your behavior. Healthline. https://www.healthline.com/health-news/ozempic-personality-change

• 6.

  Vinelli, V., De Lorenzo, R., & Rovere Querini, P. (2026, May 12–15). AI-based monitoring reveals protein deficiencies in people taking GLP-1 receptor agonists for weight loss. European Congress on Obesity, Istanbul, Turkey. https://www.eurekalert.org/news-releases/1123350

• 7.

  Christensen, S., Robinson, K., Thomas, S., & Williams, D. R. (2024). Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obesity Pillars, 11, Article 100121. https://www.sciencedirect.com/science/article/pii/S2667368124000238

• 8.

  Fink, B. D., Herlein, J. A., Guo, D. F., Kulkarni, C., Weidemann, B. J., Yu, L., Grobe, J. L., Rahmouni, K., Kerns, R. J., & Sivitz, W. I. (2014). A mitochondrial-targeted coenzyme Q analog prevents weight gain and ameliorates hepatic dysfunction in high-fat-fed mice. Journal of Pharmacology and Experimental Therapeutics, 351(3), 699–708. https://pmc.ncbi.nlm.nih.gov/articles/PMC4244581/

• 9.

  Maharjan, S. (2026, June 13). Exercise decreases among people taking GLP-1 medication. ENDO 2026, The Endocrine Society's Annual Meeting, Chicago, IL. https://www.endocrine.org/news-and-advocacy/news-room/2026/maharjan-press-release-endo-2026

• 10.

  Liu, Y., Wang, Y., Bi, Y., Fan, W., Li, X., Zheng, Q., & Zhu, D. (2014). Liraglutide exerts antidiabetic effect via PTP1B and PI3K/Akt2 signaling pathway in skeletal muscle of KKAy mice. International Journal of Endocrinology, 2014, Article 638712. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144308/

• 11.

  Hinte, L. C., Castellano-Castillo, D., Ghosh, A., Melrose, K., Gasser, E., Noé, F., Massier, L., Dong, H., Sun, W., Hoffmann, A., Wolfrum, C., Rydén, M., Mejhert, N., Blüher, M., & von Meyenn, F. (2024). Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature, 636, 457–465. https://doi.org/10.1038/s41586-024-08165-7

• 12.

  Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism, 164, Article 156113. https://www.sciencedirect.com/science/article/abs/pii/S002604952400341X

• 13.

  Broome, S. C., Woodhead, J. S. T., & Merry, T. L. (2021). Mitochondria-targeted antioxidant supplementation improves 8 km time trial performance in middle-aged trained male cyclists. Journal of the International Society of Sports Nutrition, 18(1), Article 58. https://doi.org/10.1186/s12970-021-00454-0